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Abstract
Background: Improved influenza vaccines are needed to reduce influenza-associated complications in older adults.
The aim of this study was to identify the optimal formulation of adjuvanted seasonal influenza vaccine for use in
elderly people.
Methods: This observer-blind, randomized study assessed the optimal formulation of adjuvanted seasonal influenza
vaccine based on immunogenicity and safety in participants aged ≥65 years. Participants were randomized
(~200 per group) to receive one dose of non-adjuvanted vaccine or one of eight formulations of vaccine
formulated with a squalene and tocopherol oil-in-water emulsion-based Adjuvant System (AS03C, AS03B or AS03A,
with 2.97, 5.93 and 11.86 mg tocopherol, respectively) together with the immunostimulant monophosphoryl lipid A
(MPL, doses of 0, 25 or 50 mg). Hemagglutination-inhibition (HI) antibody responses and T-cell responses were
assessed on Day 0 and 21 days post-vaccination. The ratio of HI-based geometric mean titers in adjuvanted versus
non-adjuvanted vaccine groups were calculated and the lower limit of the 90% confidence interval was
transformed into a desirability index (a value between 0 and 1) in an experimental domain for each vaccine strain,
and plotted in relation to the AS03 and MPL dose combination in the formulation. This model was used to assess
the optimal formulation based on HI antibody titers. Reactogenicity and safety were also assessed. The
immunogenicity and safety analyses were used to evaluate the optimal formulation of adjuvanted vaccine.
Results: In the HI antibody-based model, an AS03 dose–response was evident; responses against the A/H1N1 and
A/H3N2 strains were higher for all adjuvanted formulations versus non-adjuvanted vaccine, and for the
AS03A-MPL25, AS03B-MPL25 and AS03B-MPL50 formulations against the B strain. Modelling using more stringent
criteria (post hoc) showed a clear dose-range effect for the AS03 component against all strains, whereas MPL
showed a limited effect. Higher T-cell responses for adjuvanted versus non-adjuvanted vaccine were observed for
all except two formulations (AS03C and AS03B-MPL25). Reactogenicity increased with increasing AS03 dosage, and
with MPL. No safety concerns were raised.
Conclusions: Five formulations containing AS03A or AS03B were identified as potential candidates to improve
immune responses to influenza vaccination; AS03B without MPL showed the best balance between improved
immunogenicity and acceptable reactogenicity.
Trial registration: This trial is registered at ClinicalTrials.gov, NCT00540592
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Background
A significant number of the seasonal influenza-associated
hospitalizations in the United States occur among older
adults, and influenza-associated mortality also dispropor-
tionately affects this age group [1,2]. Inactivated trivalent
influenza vaccines have been available for over 60 years,
but are reported to be less effective in older adults than in
younger adults. This is generally attributed to the weaker
immune responses to vaccination in older individuals due
to an age-related decline in immune function [3-5]. This
immunosenescence may also underlie the increased sever-
ity of influenza-related complications observed in older
people [5]. Nonetheless, influenza vaccination remains a
cost-saving medical intervention in older adults that re-
sults in significant reductions in hospitalizations and
deaths due to complications of influenza illness [6-8].
Given the influenza-related morbidity and mortality
rates in older people despite widespread vaccination, there
is clearly a need to develop improved influenza vaccines
that are more effective in this vulnerable population. Strat-
egies to enhance vaccine immunogenicity and overcome
the limitations of immunosenescence include the use of
high antigen doses and the formulation of vaccine with an
adjuvant. For several decades, aluminum salt was the only
adjuvant approved for human use, but this failed to im-
prove the immunogenicity of influenza vaccines [9]. Re-
cent advances in vaccine technology have led to the
incorporation of new adjuvants or Adjuvant Systems into
influenza vaccines; these include oil-in-water emulsions
containing squalene, a naturally occurring triterpene and a
key precursor in hepatic cholesterol biosynthesis, together
with non-ionic surfactant emulsifiers. The squalene-based
oil-in-water adjuvant MF59™ is reported to improve the
immunogenicity of seasonal influenza vaccines com-
pared with non-adjuvanted vaccine [10], and a
tocopherol-based oil-in-water Adjuvant System (AS03)
is currently licensed for use with avian-origin H5N1
(Prepandrix™, a trade mark of the GlaxoSmithKline
group of companies) and swine-origin A(H1N1)pdm09
(Pandemrix™, a trade mark of the GlaxoSmithKline
group of companies) pandemic influenza vaccines [11].
Prepandrix™ and Pandemrix™ have been shown to im-
prove immunogenicity compared with non-adjuvanted
vaccine in healthy adults, and are highly immunogenic
in elderly populations [12-16]. More recently, an AS03-
adjuvanted, low antigen dose (15 μg/strain) seasonal in-
fluenza vaccine was compared with a licensed seasonal
influenza vaccine (45 μg antigen: 15 μg/vaccine), and
immunogenicity with the low dose adjuvanted vaccine was
shown to be non-inferior to the ‘normal dose’ non-
adjuvanted vaccine in people aged ≥60 years [17]. There-
fore, it is possible that adjuvantation may enhance
immunogenicity beyond that provided by existing vac-
cines in older people.
Oil-in-water emulsions can also accommodate add-
itional adjuvant-active molecules, such as monophos-
phoryl lipid A (MPL). MPL is a nontoxic derivative of
lipopolysaccharide from Salmonella minnesota and a
powerful stimulator of the immune system that is known
to act as a toll-like receptor agonist [18]. MPL has been
used as a component of a hepatitis B vaccine (approxi-
mately 44 900–224 500 doses administered since licensure
up to 1st February 2012) and a human papillomavirus vac-
cine (approximately 9.6–28.95 million doses up to 17th
November 2011) [18]. These MPL-containing vaccines
were well-tolerated with local reactogenicity symptoms
generally mild to moderate in intensity and of a short dur-
ation, and no safety concerns were raised in clinical trials
[19,20]. Based on the enhanced immunogenicity reported
for both MPL and AS03, we were interested to know
whether the addition of MPL would further enhance the
immune system response to AS03.
The objective of this study was to identify an optimal
formulation of adjuvanted influenza vaccine for use in
older adults. Eight different formulations of seasonal in-
fluenza vaccine, adjuvanted with AS03 oil-in-water
emulsion with or without MPL, were evaluated in adults
aged 65 years and older with regard to immunogenicity,
safety and reactogenicity. The control vaccine was a




The aim of this observer-blind, randomized study was to
select the optimal doses of both AS03 and MPL to be used
in an adjuvanted influenza vaccine for use in older people.
The immunogenicity, reactogenicity and safety of different
formulations of adjuvanted influenza vaccine administered
to participants aged ≥65 years were evaluated and com-
pared with non-adjuvanted influenza vaccine. The primary
outcome was hemagglutination-inhibition (HI) based im-
munogenicity against all three vaccine strains at 21 days
after vaccination. A contour plot model was used to assess
the optimal adjuvanted formulation based on HI antibody
titers. Secondary objectives included assessment of cell-
mediated responses, safety and reactogenicity.
Vaccines
The split virus influenza vaccine (Fluarix™, a trade mark of
the GlaxoSmithKline group of companies) was formulated
with eight different adjuvants, or given as plain vaccine
(hereafter, non-adjuvanted). All vaccines contained 15 μg
hemagglutinin antigen (HA) from three influenza strains
(45 μg HA in total): A/Solomon Islands/03/2006 (IVR-
145) (H1N1 strain), A/Wisconsin/67/2005 (NYMC-
X161B) (H3N2 strain) and B/Malaysia/2506/2004 (B
strain). The compositions of the AS03 Adjuvant Systems
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used for the eight adjuvanted formulations are shown in
Table 1. Each of the adjuvanted influenza vaccines were
presented as a vial containing the antigens and a syringe
containing the adjuvant. The contents of the pre-filled syr-
inge, containing the adjuvant, was injected into the vial
that contained the antigens, and after mixing, the entire
contents were withdrawn into the syringe to give one
0.7 mL dose of reconstituted, adjuvanted influenza vac-
cine. The non-adjuvanted vaccine was presented as a pre-
filled syringe (0.5 mL). All vaccines were prepared and
administered intramuscularly by unblinded personnel
who took no further part in the study procedures; partici-
pants and personnel involved in assessment of safety, data
processing and analysis were blind to vaccine allocation.
Participants and study design
The study was conducted in Germany (21 centers: 11 gen-
eral practices, 2 centers, 2 not specified), the Netherlands
(2 centers: 1 clinical research center, 1 Municipal Health
Service center), Sweden (3 centers: 2 hospital clinics, 1
clinical research center) and the United Kingdom (5 clin-
ical research centers). The first participant was enrolled in
October 2007, and the final study visit was in June 2008.
Volunteers were eligible to participate in the study if they
were aged 65 years or older, were free of an acute aggrava-
tion of health status as established by clinical evaluation
and provided written informed consent. Besides inclusion
of participants from the target age group of ≥65 years, a
control group of young adults aged 18–40 years old was in-
cluded as a reference group to compare the immune re-
sponse and reactogenicity of the adjuvanted vaccines.
Eligible participants aged 65 years or older were ran-
domized to receive one dose of non-adjuvanted vaccine or
one of eight different formulations of adjuvanted influenza
vaccine (Table 1); the group aged 18–40 years received
non-adjuvanted vaccine. Vaccine allocation was performed
by the sponsor using a central internet randomization sys-
tem. The nine groups aged ≥65 years and the 18–40 years
group were randomized 1:1:1:1:1:1:1:1:1:1. A randomi-
zation algorithm used a blocking scheme to ensure a bal-
ance between the vaccines, and stratified the study groups
(aged ≥65 years) by age (65–74 years [65%] and ≥75 years
[35%]). The algorithm incorporated a minimization pro-
cedure to account for center. The study was observer-
blind for participants aged ≥65 years and open-label for
participants aged 18–40 years.
The protocol and study documents were approved by
the appropriate Independent Ethics Committees or Insti-
tutional Review Boards in each country (Ethikkommission
bei der Sächsischen Landesärztekammer, Oxfordshire
Research Ethics Committee B, Regionala Etikpröv-
ningsnämnden I Uppsala and Centrale Commissie
Mensgebonden Onderzoek) (Additional file 1). The study
was conducted in accordance with the Declaration of
Helsinki. GlaxoSmithKline Biologicals SA sponsored the
study and was involved in all stages of the study con-
duct, including analysis of the data. All authors had full
access to the data and were involved in the analysis of
the data and preparation of the manuscript. The trial is
registered at ClinicalTrials.gov, NCT00540592. A sum-
mary of the protocol may be found at: http://www.gsk-
clinicalstudyregister.com/ (study ID 110847).
Immunogenicity
Blood samples were collected for immunological testing,
before (Day 0) and 21 days after (Day 21) vaccination. All
assays were performed in a GlaxoSmithKline Vaccines
central laboratory or in a validated laboratory designated
by GlaxoSmithKline Vaccines, using standardized, vali-
dated procedures with validated controls.
HI assays were performed on serum samples as de-
scribed previously using chicken red blood cells [21]. Anti-
body responses were described as geometric mean titer
(GMT; anti-log of the mean of the log-10 transformed ti-
ters), seroprotection rate (SPR; proportion of participants
with post-vaccination titer ≥1:40), seroconversion rate
(SCR; proportion of participants with titer <1:10 at
baseline with post-vaccination titer of ≥1:40, or pre-
vaccination titer of ≥1:10 and ≥4-fold increase post-
vaccination), and seroconversion factor (SCF; geometric
mean of the within subject ratios of reciprocal HI antibody
titers for post-vaccination versus pre-vaccination).
Cell mediated immune (CMI) responses were based on
T cell responses, as described previously [22,23]. Briefly,
blood samples were collected in heparinized tubes and
kept at ambient temperature (15–25°C), until peripheral
blood mononuclear cells (PBMCs) were isolated (within
24 h of blood sampling) and frozen at −80°C. Immuno-
logical assays were performed later in test runs with
PBMC/T cells in one run with adequate control cells.
PBMCs were re-stimulated ex vivo by incubation with
influenza antigen in the presence of co-stimulatory
Table 1 Composition of the adjuvanted influenza vaccine
formulations









All formulations of the vaccine contained AS03, which is a squalene and
α-tocopherol oil-in-water emulsion-based Adjuvant System. MPL is
3-O-desacyl-4’- monophosphoryl lipid A.
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antibodies to CD28 and CD49d, and Brefeldin A. Cells were
subsequently harvested, stained for surface markers (CD4)
and fixed. Fixed cells were then permeabilized and stained
with antibodies specific for interferon-gamma (IFN-γ),
interleukin-2 (IL-2), tumor necrosis factor-alpha (TNF-α)
or CD40L, and analyzed by cytofluorometry. Results were
expressed as the frequencies of influenza-specific CD4 T
cells producing at least two response markers.
Reactogenicity and safety
Participants used diary cards to record the occurrence
and intensity of injection site solicited adverse events
(ecchymosis, pain, redness and swelling) and systemic
solicited adverse events (arthralgia, fatigue, headache,
myalgia, nausea, shivering and fever) during the first 7
days after vaccination. The diameters of any injection
site ecchymosis, redness or swelling were recorded, with
grade 3 defined as >100 mm. Daily body temperature
was also recorded; grade 3 fever was defined as body
temperature ≥39.0–40.0°C, and grade 4 fever as body
temperature >40.0°C. The intensities of other adverse
events were recorded according to a standard 0 to 3
grade scale: “absent”, “easily tolerated”, “interferes with
normal activity” or “prevents normal activity”. Data were
also collected on the occurrence and intensity of any
spontaneous unsolicited signs. Data on serious adverse
events (SAEs) were collected prospectively from 21 days
to 180 days after vaccination.
Statistical analyses
The target sample size was 2000 participants, including
200 participants in the 18–40 years stratum, 1170 partic-
ipants in the 65–74 years stratum, and 630 participants
in the ≥75 years stratum. The expected precision of the
relative immune response estimation was presented for
190 evaluable participants in each group (assuming that
about 5% of subjects would not be evaluable for the im-
munogenicity endpoints). This was based on computa-
tions of the lower limits of the 90% confidence interval
(CI) of the geometric mean titer (GMT) ratio (AS03
adjuvanted vaccine over non-adjuvanted vaccine in
the ≥65 year group), according to various expected
values for the GMT ratio estimate and various standard
deviations at the log10-scale (one-sided alpha = 5%).
Reactogenicity and safety was assessed in the total vacci-
nated cohort including all participants who were vacci-
nated. HI antibody responses were evaluated in the per
protocol immunogenicity cohort including vaccinated par-
ticipants who complied with the study protocol and for
whom a serological sample was available at a given time
point. CMI responses were assessed in a subset of 500 par-
ticipants from pre-specified study centers; the analysis was
performed on the per protocol cell mediated immunogen-
icity cohort including vaccinated participants in the CMI
subset who complied with the study protocol and for whom
a serological sample was available at a given time point.
HI-based GMT, SCR, SCF, and SPR were calculated
with 95% CIs as defined by regulatory criteria [24,25].
GMT ratios for each formulation versus non-adjuvanted
vaccine were calculated with two-sided 90% CIs. The
frequencies of immune response marker-positive CD4 T
cells producing at least two immune response markers
(all doubles) were calculated as medians with interquar-
tile ranges for Days 0 and 21. The reactogenicity and
safety endpoints were the percentages of participants
reporting an event with 95% CIs.
Immunogenicity model
A multi-criteria decision-making approach was used to
identify which vaccine combination of AS03 and MPL
would have the most desirable immune response 21 days
after vaccination compared with the non-adjuvanted
vaccine in participants aged ≥65 years. HI antibody titers
were used to produce a contour plot of overall desirabil-
ity to identify the region of the experimental domain
with the highest desirability, i.e. the region containing
the formulations demonstrating the best HI immuno-
genicity for the three vaccine strains. Within the domain
of variation of both AS03 and MPL, the least square
means of the log titers and the standard errors were esti-
mated using a multiple regression model. The arithmetic
mean of the log transformed HI titers for the non-
adjuvanted vaccine was calculated as well as its standard
error. Then the 90% CI lower limits (LL) of the ratio for
each AS03 and MPL combination versus the non-
adjuvanted vaccine were transformed into a desirability
index between 0 and 1 using a sigmoidal Derringer func-
tion. Each LL was transformed to a value between 0 and
1, where 0 indicated an undesirable relative immune re-
sponse, and 1 a highly desirable relative immune re-
sponse. In the prospective analysis, an LL equal to 1.0
was transformed into a desirability equal to 0.5. A post
hoc analysis was also performed using more stringent
criteria, where an LL equal to 1.5 was transformed in de-
sirability equal to 0.5 (applied only for A strains).
An overall desirability index was obtained by taking a
weighted geometric mean of the three desirability in-
dexes associated to the three vaccine strains. A contour
plot of the desirability indexes in the experimental do-
main was then built for each strain and for all three
strains using a color spectrum from red denoting the
most undesirable index to purple denoting the most de-
sirable index. Based on the color contour plots combin-
ing the three strains, formulations were then ranked
according to the overall desirability index. The GMTs,
SCRs, SCFs, and SPRs of the formulations ranked most
desirable were further evaluated to assess the adequacy
of the expectation.
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Results
A total of 2008 participants were enrolled, including
203 aged 18–40 years, 1177 aged 65–74 years, and 627
aged ≥75 years, of which 1997 participants completed the
study visit at Day 21 (Figure 1). Ninety participants were
eliminated from the per protocol immunogenicity cohort
for HI for non-compliance with the protocol (Figure 1).
The mean age of the participants at the time of vaccin-
ation was 72.7 ± 5.66 years (median 72.00 years) for the
participants aged ≥65 years and 27.4 ± 6.25 years (median
Figure 1 Participant flow. Footnote: TVC, total vaccinated cohort; all participants received inactivated trivalent influenza vaccine; control ≥65
years and control 18–40 years received non-adjuvanted vaccine; eight groups aged ≥65 years received vaccine formulated with an adjuvant.
AS03 is a squalene and α-tocopherol oil-in-water emulsion-based Adjuvant System (tocopherol content: A, 11.86 mg; B, 5.93 mg; C, 2.97 mg);
MPL is 3-O-desacyl-4’- monophosphoryl lipid A (MPL content: 25, 25 μg; 50, 50 μg).
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27.00 years) for participants aged 18–40 years. Excluding
the 18–40 years group, the mean age at vaccination in the
individual vaccine groups ranged from 72.4–73.0 years in
the total vaccinated cohort (Table 2). The majority of par-
ticipants (>97%) were White-Caucasian. The ≥65 years vac-
cine groups were balanced for demographic characteristics.
Humoral immunogenicity
The HI antibody responses to each of influenza vaccine
strains in each study group are shown in Figure 2 (data
are detailed in Additional file 2). In recipients of non-
adjuvanted vaccine, stronger immune responses were
seen in the younger group than in the ≥65 years group;
Day 21 GMTs for ≥65 years versus 18–40 years were
59.6 vs. 271.6 for the A/Solomon Islands H1N1 strain,
186.7 vs. 380.2 for the A/Wisconsin H3N2 strain, and
153.0 vs. 281.9 for the B/Malaysia strain.
Immunogenicity modelling
The GMT ratios for adjuvanted versus non-adjuvanted
vaccine are shown in Figure 3. Contour plots are shown in
Figure 4. A high desirability index was observed in the
contour plots for the A/Solomon Islands H1N1 and A/
Wisconsin H3N2 strains at all AS03 and MPL doses com-
pared with the non-adjuvanted ≥65 year group in all the
different formulation groups. All 90% CIs had a LL >1
which was higher than the predefined highest desirability
score. In contrast, the contour plot for the B/Malaysia
strain showed that the highest desirability was obtained
with formulations containing higher concentrations of
AS03 (AS03B and AS03A) together with MPL. This was
associated with the higher geometric mean ratio with
LL >1.0 for the AS03A-MPL25, AS03B-MPL25 and
AS03B-MPL50 formulations. These two observations lead
to the conclusion that only the B strain contributed to the
overall ranking.
More discriminative contour plots were generated
based on post hoc analyses performed with more strin-
gent conditions for the A/Solomon Islands H1N1 and
A/Wisconsin H3N2 strains (a desirability of 0.5 was as-
sociated with a LL=1.5) (Figure 5). A clear dose-range ef-
fect was observed for the AS03 component, whereas
MPL showed limited or no effect. This was reflected in
the post hoc plot for all three vaccine strains (Figure 5).
Overall, a dose-range effect of the oil-in-water compo-
nent was found, with the weakest immunogenicity
exhibited by the AS03C formulations. When all three
strains were considered together, the desirability plots
indicated that the AS03A-MPL25 formulation had the
highest score (Figure 5C).
Cell-mediated immunogenicity
The frequencies of influenza-specific CD4 T cells produ-
cing at least two immune response markers in each group,















N=204 N=202 N=198 N=202 N=199 N=199 N=202 N=198 N=200 N=203
Age at vaccination (years)
Mean±SD 72.7±5.75 72.9±6.09 72.6±5.67 72.6±5.16 72.5±5.66 73.0±6.03 72.4±5.62 72.7±5.56 72.7±5.43 27.4±6.25
Median
(min–max)
72.0 71.0 72.0 72.0 72.0 72.0 71.0 72.0 72.0 27.0
(63–91) (64–91) (65–94) (65–87) (65–91) (62–95) (65–90) (65–88) (65–89) (18–40)
Gender, n (%)
Female 95 (46.6) 100 (49.5) 96 (48.5) 109 (54.0) 89 (44.7) 95 (47.7) 105 (52.0) 102 (51.5) 90 (45.0) 103 (50.7)
Male 109 (54.3) 102 (50.5) 102 (51.5) 93 (46.0) 110 (55.3) 104 (52.3) 97 (48.0) 96 (48.5) 110 (55.0) 100 (49.3)
Geographic Ancestry, n (%)
African/African
American
1 (0.5) 0 2 (1.0) 0 0 1 (0.5) 0 1 (0.5) 0 2 (1.0)
Asian–Central/
South
1 (0.5) 0 0 0 0 0 0 0 0 0
Asian–South East 1 (0.5) 1 (0.5) 2 (1.0) 0 0 1 (0.5) 2 (1.0) 0 0 0
White–Arabic/
North African
2 (1.0) 1 (0.5) 1 (0.5) 1 (0.5) 1 (0.5) 1 (0.5) 0 3 (1.5) 0 2 (1.0)
White–Caucasian/
European
199 (97.5) 199 (98.5) 193 (97.5) 201 (99.5) 197 (99.0) 195 (98.0) 198 (98.0) 194 (98.0) 200 (100.0) 197 (97.0)
Other 0 1 (0.5) 0 0 1 (0.5) 1 (0.5) 2 (1.0) 0 0 2 (1.0)
TVC, total vaccinated cohort; All participants received inactivated trivalent influenza vaccine, non-adjuvanted (≥65 years and 18–40 years) or formulated with an
adjuvant. AS03 is a squalene and α-tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C);
MPL is 3-O-desacyl-4’- monophosphoryl lipid A: 25 μg (MPL-25) or 50 μg (MPL-50).
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at Day 0 and Day 21 following stimulation by the three
pooled strains are shown in Figure 6. Vaccination with all
except two of the formulations (AS03C and AS03B-
MPL25) resulted in the observation of higher CD4 T cell
responses compared with the non-adjuvanted ≥65 year
group following ex vivo stimulation with all three pooled
strains. For three of the formulations (AS03A, AS03B and
AS03A-MPL25), the pooled influenza strain-specific CD4
T cell responses were also found to be higher than the
non-adjuvanted 18–40 years group.
Safety and reactogenicity
During the 21-day follow-up period, 19 participants
reported 25 SAEs, ranging from 0–2.0% per study group
(Table 3). The outcome of one SAE (pancreatic tumor in
the AS03B-MPL25 group diagnosed 17 days after the
first dose of vaccine), which led to withdrawal from the
study, was subsequently fatal, but judged by the investi-
gator not to be related to vaccination. Two further par-
ticipants (1 each in the AS03B and AS03B-MPL50
groups) withdrew from the study due to SAEs (atrial fib-
rillation/ischemic stroke and myocardial infarction) that
were not related to vaccination. One SAE (chest pain)
was considered by the investigator to be possibly caus-
ally related to vaccination, since the chest pain started
on the day of vaccination (AS03B-MPL50). This event
resolved within 9 days. Between Days 21 and 179, 112
participants reported 134 SAEs, ranging from 1.5–9.5%
per study group. There were 4 fatal SAEs during this
time, none of which were considered to be related to
vaccination (1 participant in each of the AS03C and
AS03C-MPL25 groups and 2 participants in the AS03B-
MPL50 group). Two additional participants withdrew
from the study due to a SAE (worsening of gout and ab-
dominal pain). One SAE (chronic myelomonocytic
leukemia) was considered by the investigator to be pos-
sibly related to vaccination, as the participant felt that
there was an association between the time of vaccin-
ation (non-adjuvanted ≥65 year group) and the develop-
ment of symptoms. The onset of the SAE was Day 69,
and the SAE had not recovered/resolved by the end of
the study.
The reactogenicity profile during the 7 days following
vaccination is shown in Figure 7. The percentage of partic-
ipants reporting at least one local symptom (solicited or
unsolicited) ranged from 38.7% to 67.7% in the adjuvanted
vaccine groups, 18.0% reported a symptom in the non-
adjuvanted ≥65 year group, and 45.8% in the non-
adjuvanted 18–40 years group. For systemic symptoms,
between 30.9% and 57.1% of participants reported a symp-
tom in the adjuvanted vaccine groups, 25.0% in the
non-adjuvanted ≥65 year group, and 45.3% in the non-
adjuvanted 18–40 years group. The incidence of grade 3
events and fever >40°C was between 0 and 5.0% for all
groups. A dose-range effect may be observed on the
reactogenicity of the adjuvanted formulations, with a trend
towards increasing incidence of symptoms with increasing
AS03 content and with the presence of MPL. This was
also reflected in the solicited symptom profiles.
Pain was the most common solicited local symptom
(Additional file 3). The maximum number of reports
(60.4%) was in the AS03A-MPL25 group, with 16.0% in
the non-adjuvanted ≥65 year group, and 46.3% in the non-
adjuvanted 18–40 years group. The three most commonly
reported general solicited symptoms (Additional file 4)
were myalgia (maximum: 33.3% in the AS03A-MPL25
group vs. 9.5% in the ≥65 year group and 19.9% in the 18–
40 years group), fatigue (maximum: 31.8% in the AS03B-
MPL50 group vs. 12.0% in the non-adjuvanted ≥65 year
group and 20.4% in the 18–40 years group) and headache
(maximum: 27.8% in the AS03A-MPL25 group vs. 11.5%
in the non-adjuvanted ≥65 year group and 22.4% in the
18–40 years group).
Discussion
This randomized study assessed eight different formula-
tions of influenza vaccine, adjuvanted with AS03 (squa-
lene and tocopherol oil-in-water emulsion) with or
without MPL, and a contour plot model was used to
identify an optimal formulation for vaccination of older
adults based on immunogenicity. Age-related declines in
innate, and adaptive humoral and cell-mediated immun-
ity, is thought to impair the ability to resist influenza in-
fection and response to vaccination [26,27], therefore,
the rationale for formulating seasonal influenza vaccine
with the adjuvant was to enhance immunogenicity and
potentially improve protection of existing vaccines.
HI antibody responses with non-adjuvanted vaccine in
the younger (18–40 years) control group were consistent
with responses reported by randomized immunogenicity
trials with this vaccine (Fluarix™), and responses in older
(≥65 years) people to non-adjuvanted control vaccine
(See figure on previous page.)
Figure 2 HI antibody responses in the per protocol immunogenicity cohort : Geometric mean titers (A); Seroconversion rates (B);
Seroprotection rates (C); Seroconversion factor (D). Footnote: HI, Hemagglutination-inhibition; TVC, total vaccinated cohort; All participants
received inactivated trivalent influenza vaccine, non-adjuvanted (≥65 years and 18–40 years) or formulated with an adjuvant. AS03 is a squalene
and α-tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is
3-O-desacyl-4’- monophosphoryl lipid A: 25 μg (MPL-25) or 50 μg (MPL-50).
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Figure 3 HI GMT ratio for adjuvanted versus non-adjuvanted formulation in the per protocol immunogenicity cohort against A/H1N1
(A), A/H3N2 (B), and influenza B strain (C). Footnote: HI, hemagglutination-inhibition; All participants received inactivated trivalent influenza
vaccine, non-adjuvanted (≥65 years and 18–40 years) or formulated with an adjuvant. AS03 is a squalene and α-tocopherol oil-in-water
emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is 3-O-desacyl-4’- monophosphoryl lipid
A: 25 μg (MPL-25) or 50 μg (MPL-50).
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were relatively low; seroprotection rates (proportion with
titer ≥1:40) were 92.4–100% in the 18–40 year old group
compared with 70.2–97.3% in the older group. In older
participants, HI antibody responses to all adjuvanted for-
mulations appeared slightly higher than responses to non-
adjuvanted vaccine; however, because 200 participants per
group did not provide sufficient power to compare the
groups, a statistical model based on HI GMTs was used to
objectively rank the different formulations. In the model,
the lower limit of the 90% CI for the GMT ratio for each
adjuvanted formulation versus non-adjuvanted was used
to assign a ‘desirability index’ for each formulation, which
involved transforming the CI to a value between 0 and 1,
where 0 was undesirable and 1 was most desirable. Con-
tour plots were used to characterize the desirability of
each formulation based on the immunogenicity against
each vaccine strain, and all three strains.
The contour plots showed that the effect of adju-
vantation on the humoral response to vaccination was
strain-dependent. For HI antibody responses against the
A/Solomon Islands H1N1 and A/Wisconsin H3N2 strains,
all AS03 formulations had the highest desirability, but for
the B/Malaysia strain, an increase in desirability was ob-
served when the AS03 dose approached a maximum level.
The model also indicated that whereas inclusion of MPL
appeared to increase desirability based on HI responses
against the B/Malaysia strain, no clear effect was shown
for the A/Solomon Islands H1N1 and the A/Wisconsin
H3N2 strains.
The unexpected observations for the influenza A strains
lead to a lack of discrimination within the initial plots, so
we performed post hoc analyses applying more stringent
criteria to further evaluate potential differences between
the formulations. In the post hoc model, a higher AS03
dose, but not MPL, increased the desirability based on HI
responses against both of the influenza A strains. Overall
for the three vaccine strains, the dosage of MPL had a lim-
ited effect in discriminating the formulations in terms of
HI response despite the fact that the AS03A-MPL25 for-
mulation had the highest score. The contour plots showed
that AS03 dosage had a clear effect with relatively high
AS03 content formulations needed to achieve an optimal
HI antibody response. Increased immune responses with
increasing AS03 dosage was further confirmed by the HI
Figure 4 Contour plots of HI antibody responses in the per protocol immunogenicity cohort against A/H1N1 (A), A/H3N2 (B), influenza
B (C), and all vaccine strains (D). Footnote: HI, hemagglutination-inhibition; GMT ratios for each adjuvanted formulation versus non-adjuvanted
vaccine calculated with two-sided 90% Confidence Interval (CI); the lower limits (LL) of CI were transformed into a desirability index between 0
and 1 using a sigmoidal Derringer function; each LL was transformed to a value between 0 and 1, where 0 indicated an undesirable relative
immune response, and 1 a highly desirable relative immune response. LL equal to 1.0 was transformed into a desirability equal to 0.5. The colors
range from red (least desirable) to purple (most desirable).
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immunogenicity results, although the sample size in each
group did not allow definite statistical conclusions.
In addition to the provision of CD4 T cell help for B cell
differentiation, both CD4 effector and memory T cells ap-
pear to have multifaceted roles in the protective responses
to influenza infection [23,28]. CD4+ T-helper cells are po-
larized into T helper 1 or T helper 2 cells, and T helper 1
cells predominantly secrete IFN-γ, which activates macro-
phages and facilitates clearance of intracellular pathogens
[29-32]. Impairment of T cell responses due to aging is
therefore considered to be an important factor that limits
the responses to vaccination, and it has been proposed
that correlates of vaccine-mediated protection against
influenza in older adults should include measures of
cell-mediated responses [5,33]. In our study, adjuvanted
vaccine also enhanced CD4 T cell-mediated responses
to all three vaccine strains compared with non-
adjuvanted vaccine in elderly people, with the most
marked impact on responses to the pooled strains was
observed for the AS03A, AS03B and AS03A-MPL25 for-
mulations. This indicates that the presence of MPL does
not appear, in this setting, to be essential to achieve
maximal enhancement of CD4 T cell responses to influ-
enza antigens.
Oil-in-water adjuvants have been shown to enhance
the response to vaccination by triggering chemokine
production resulting in recruitment of immunocompetent
cells to the injection site, cell maturation into a dendritic
phenotype, the stimulation of antigen uptake into these
cells, and facilitation of subsequent migration to the
lymph nodes [22,34-36]. The adjuvant activity of AS03 is
highly dependent on the presence of the immuno-
stimulant α-tocopherol (an isoform of vitamin E) [37],
which distinguishes AS03 from other oil-in-water
emulsion-based adjuvants. The oil-in-water adjuvant
MF59™ contains polysorbate 80, sorbitan trioleate,
trisodium citrate dehydrate, citric acid monohydrate, and
has been shown to enhance immune responses to seasonal
influenza vaccine compared with non-adjuvanted vaccine
[10,38]. An MF59™-adjuvanted influenza vaccine (Fluad™)
is licensed and widely used, and has been shown to sig-
nificantly reduce hospitalization for influenza and pneu-
monia compared with non-adjuvanted vaccine in elderly
people [39]. However, there have been no prospective,
Figure 5 Contour plots (post-hoc) of HI antibody responses in the per protocol immunogenicity cohort against A/H1N1 (A), A/H3N2
(B), and all three vaccine strains (C). Footnote: HI, hemagglutination-inhibition; GMT ratios for each adjuvanted formulation versus non-
adjuvanted vaccine calculated with two-sided 90% Confidence Interval (CI); the lower limits (LL) of CI were transformed into a desirability index
between 0 and 1 using a sigmoidal Derringer function; each LL was transformed to a value between 0 and 1, where 0 indicated an undesirable
relative immune response, and 1 a highly desirable relative immune response. For A/H1N1 and A/H3N2, an LL equal to 1.5 was transformed in
desirability equal to 0.5. The colors range from red (least desirable) to purple (most desirable).
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randomized clinical trials of vaccine efficacy of this for-
mulation in people aged ≥65 years [10].
Seasonal influenza vaccines are licensed based on dem-
onstrating the induction of HI antibody titers above a de-
fined threshold; a HI antibody titer of 1:40 is generally
accepted as corresponding to a 50% reduction in the risk
of influenza, which is based on a challenge study
conducted forty years ago [40]. However, although
humoral immune responses measured by HI may be a
good correlate of protection in younger adults, it has
been suggested that HI titers may not be an adequate
surrogate for protection against influenza in older
adults. Indeed, vaccine efficacy data from field trials are
considered to provide a more meaningful measure of
the benefits of influenza vaccination than serological
data in elderly populations. Based on the results of our
Phase II study, AS03B (5.93 mg tocopherol) without
MPL was selected for further evaluation as it provided
the best balance between the immune response and
reactogenicity; AS03-adjuvanted versus non-adjuvanted
trivalent influenza vaccine was evaluated in a Phase III
study including 43,000 people in 15 countries,
representing the largest field study to date to assess in-
fluenza vaccine efficacy in people aged ≥65 years
(NCT00753272). In addition to vaccine efficacy, the
study evaluated clinical outcomes, immunogenicity,
reactogenicity and safety [41].
In addition to enhancing immunogenicity, the incorp-
oration of adjuvant components into a vaccine can also
have an impact on the safety/reactogenicity profile. We
observed that in the 7 days following vaccination, over-
all reactogenicity was higher for the eight adjuvanted in-
fluenza formulations than for non-adjuvanted influenza
vaccine in ≥65 year old participants. In general, the inci-
dence of most reactions in the adjuvanted vaccine groups
remained within the same range as those induced by non-















N=204 N=202 N=198 N=202 N=199 N=199 N=202 N=198 N=200 N=203
Day 0–21 0 (0.0%) 2 (1.0%) 2 (1.0%) 3 (1.5%) 2 (1.0%) 4 (2.0%) 2 (1.0%) 4 (2.0%) 0 (0.0%) 0 (0.0%)
Day 21–179 18 (8.8%) 8 (4.0%) 16 (8.1%) 9 (4.5%) 9 (4.5%) 19 (9.5%) 5 (2.5%) 10 (5.1%) 15 (7.5%) 3 (1.5%)
All participants received inactivated trivalent influenza vaccine, non-adjuvanted (≥65 years and 18–40 years) or formulated with an adjuvant. AS03 is a squalene
and α-tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is 3-O-desacyl-4’-
monophosphoryl lipid A: 25 μg (MPL-25) or 50 μg (MPL-50).
Figure 6 Cell mediated immunogenicity in the per protocol cell mediated immunogenicity cohort. Footnote: Results for each time point are
indicated by median values with first and third quartiles. All participants received inactivated trivalent influenza vaccine, non-adjuvanted (≥65 years and
18–40 years) or formulated with an adjuvant. AS03 is a squalene and α-tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol
content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is 3-O-desacyl-4’- monophosphoryl lipid A: 25 μg (MPL-25) or 50 μg (MPL-50).
Rümke et al. BMC Infectious Diseases 2013, 13:348 Page 12 of 15
http://www.biomedcentral.com/1471-2334/13/348
adjuvanted control vaccine in the young adult group. A
dose-range effect was observed, with the highest incidence
of reactions associated with the AS03A formulations. The
presence of MPL also tended to increase reactogenicity of
the influenza vaccine. Nevertheless, the majority of adverse
events reported following administration of all eight
adjuvanted formulations were mild to moderate in nature,
and no clinically observable safety concerns were raised.
Ultimately, assuming similar safety profiles, the public ac-
ceptability of the reactogenicity profiles for the different
formulations in the days immediately following vaccination
will depend upon the extent of the clinical benefit. The se-
lection of final candidate formulations must therefore be
based on a balance between improvement in immunogen-
icity and increase in reactogenicity.
Limitations of the current study included that the
randomization procedure did not take previous vaccin-
ation history into account, or that there may have been a
tendency for more healthy participants to be recruited,
which cannot be adjusted for in the analyses. Another
possible limitation of the study is that a relatively low
sample size was used in the testing of cell-mediated im-
munity. Although it is not a limitation, it should be
noted that the GMT ratios used in the primary endpoint
was calculated using 90% CIs instead of the more usual
95% CIs. The desirability model was based only on the
GMT ratios, and the reactogenicity results were descrip-
tive. In addition, descriptive immunogenicity (SCR, SCF
and SPR) was based on HI antibody assays, as this meas-
ure is the basis of the established correlate of protection
in seasonal influenza; other measures of immunogenicity
such as microneutralization assay and single radial
haemolysis were not used.
Conclusions
Five formulations containing AS03A or AS03B with or
without MPL were considered to be potential candidates
to improve immune responses to seasonal influenza vac-
cine in older adults. The statistical model used helped
rank the different formulations with a reasonable study
sample size. For further development, AS03B without
MPL was selected as the optimal formulation for use in
the older adult population, based on the balance between
improved immunogenicity and acceptable reactogenicity.
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